178 related articles for article (PubMed ID: 32719347)
1. High-dimensional single-cell analysis delineates radiofrequency ablation induced immune microenvironmental remodeling in pancreatic cancer.
Fei Q; Pan Y; Lin W; Zhou Y; Yu X; Hou Z; Yu X; Lin X; Lin R; Lu F; Guan H; Huang H
Cell Death Dis; 2020 Jul; 11(7):589. PubMed ID: 32719347
[TBL] [Abstract][Full Text] [Related]
2. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
[TBL] [Abstract][Full Text] [Related]
3. Radiofrequency Ablation Remodels the Tumor Microenvironment and Promotes Neutrophil-Mediated Abscopal Immunomodulation in Pancreatic Cancer.
Faraoni EY; O'Brien BJ; Strickland LN; Osborn BK; Mota V; Chaney J; Atkins CL; Cen P; Rowe J; Cardenas J; Poulsen KL; Wray CJ; Thosani NC; Bailey-Lundberg JM
Cancer Immunol Res; 2023 Jan; 11(1):4-12. PubMed ID: 36367967
[TBL] [Abstract][Full Text] [Related]
4. Oncolytic herpes simplex virus HF10 (canerpaturev) promotes accumulation of CD8
Eissa IR; Mukoyama N; Abdelmoneim M; Naoe Y; Matsumura S; Bustos-Villalobos I; Ichinose T; Miyajima N; Morimoto D; Tanaka M; Fujimoto Y; Sone M; Kodera Y; Kasuya H
Int J Cancer; 2021 Jul; 149(1):214-227. PubMed ID: 33687756
[TBL] [Abstract][Full Text] [Related]
5. MTL-CEBPA Combined with Immunotherapy or RFA Enhances Immunological Anti-Tumor Response in Preclinical Models.
Huang KW; Tan CP; Reebye V; Chee CE; Zacharoulis D; Habib R; Blakey DC; Rossi JJ; Habib N; Sodergren MH
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502076
[TBL] [Abstract][Full Text] [Related]
6. A Case Report on Longitudinal Collection of Tumour Biopsies for Gene Expression-Based Tumour Microenvironment Analysis from Pancreatic Cancer Patients Treated with Endoscopic Ultrasound Guided Radiofrequency Ablation.
Lawrence PV; Desai K; Wadsworth C; Mangal N; Kocher HM; Habib N; Sadanandam A; Sodergren MH
Curr Oncol; 2022 Sep; 29(10):6754-6763. PubMed ID: 36290808
[TBL] [Abstract][Full Text] [Related]
7. Immune Adjuvant Activity of Pre-Resectional Radiofrequency Ablation Protects against Local and Systemic Recurrence in Aggressive Murine Colorectal Cancer.
Ito F; Ku AW; Bucsek MJ; Muhitch JB; Vardam-Kaur T; Kim M; Fisher DT; Camoriano M; Khoury T; Skitzki JJ; Gollnick SO; Evans SS
PLoS One; 2015; 10(11):e0143370. PubMed ID: 26599402
[TBL] [Abstract][Full Text] [Related]
8. Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer.
Zhang Y; Velez-Delgado A; Mathew E; Li D; Mendez FM; Flannagan K; Rhim AD; Simeone DM; Beatty GL; Pasca di Magliano M
Gut; 2017 Jan; 66(1):124-136. PubMed ID: 27402485
[TBL] [Abstract][Full Text] [Related]
9. Synergizing sunitinib and radiofrequency ablation to treat hepatocellular cancer by triggering the antitumor immune response.
Qi X; Yang M; Ma L; Sauer M; Avella D; Kaifi JT; Bryan J; Cheng K; Staveley-O'Carroll KF; Kimchi ET; Li G
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33115942
[TBL] [Abstract][Full Text] [Related]
10. TLR9 agonist enhances radiofrequency ablation-induced CTL responses, leading to the potent inhibition of primary tumor growth and lung metastasis.
Xu A; Zhang L; Yuan J; Babikr F; Freywald A; Chibbar R; Moser M; Zhang W; Zhang B; Fu Z; Xiang J
Cell Mol Immunol; 2019 Oct; 16(10):820-832. PubMed ID: 30467420
[TBL] [Abstract][Full Text] [Related]
11. Immune Response After Radiofrequency Ablation and Surgical Resection in Nonsmall Cell Lung Cancer.
Schneider T; Hoffmann H; Dienemann H; Herpel E; Heussel CP; Enk AH; Ring S; Mahnke K
Semin Thorac Cardiovasc Surg; 2016 Summer; 28(2):585-592. PubMed ID: 28043482
[TBL] [Abstract][Full Text] [Related]
12. Acceleration of pancreatic tumorigenesis under immunosuppressive microenvironment induced by Reg3g overexpression.
Liu X; Zhou Z; Cheng Q; Wang H; Cao H; Xu Q; Tuo Y; Jiang L; Zou Y; Ren H; Xiang M
Cell Death Dis; 2017 Sep; 8(9):e3033. PubMed ID: 28880262
[TBL] [Abstract][Full Text] [Related]
13. Discrepancies in the Tumor Microenvironment of Spontaneous and Orthotopic Murine Models of Pancreatic Cancer Uncover a New Immunostimulatory Phenotype for B Cells.
Spear S; Candido JB; McDermott JR; Ghirelli C; Maniati E; Beers SA; Balkwill FR; Kocher HM; Capasso M
Front Immunol; 2019; 10():542. PubMed ID: 30972056
[TBL] [Abstract][Full Text] [Related]
14. Remodeling of the tumor microenvironment via disrupting Blimp1
Dixon ML; Luo L; Ghosh S; Grimes JM; Leavenworth JD; Leavenworth JW
Mol Cancer; 2021 Nov; 20(1):150. PubMed ID: 34798898
[TBL] [Abstract][Full Text] [Related]
15. PD-1 Blockade Boosts Radiofrequency Ablation-Elicited Adaptive Immune Responses against Tumor.
Shi L; Chen L; Wu C; Zhu Y; Xu B; Zheng X; Sun M; Wen W; Dai X; Yang M; Lv Q; Lu B; Jiang J
Clin Cancer Res; 2016 Mar; 22(5):1173-1184. PubMed ID: 26933175
[TBL] [Abstract][Full Text] [Related]
16. Tumor microenvironment dictates regulatory T cell phenotype: Upregulated immune checkpoints reinforce suppressive function.
Kim HR; Park HJ; Son J; Lee JG; Chung KY; Cho NH; Shim HS; Park S; Kim G; In Yoon H; Kim HG; Jung YW; Cho BC; Park SY; Rha SY; Ha SJ
J Immunother Cancer; 2019 Dec; 7(1):339. PubMed ID: 31801611
[TBL] [Abstract][Full Text] [Related]
17. T-cell programming in pancreatic adenocarcinoma: a review.
Seo YD; Pillarisetty VG
Cancer Gene Ther; 2017 Mar; 24(3):106-113. PubMed ID: 27910859
[TBL] [Abstract][Full Text] [Related]
18. STING agonist inflames the pancreatic cancer immune microenvironment and reduces tumor burden in mouse models.
Jing W; McAllister D; Vonderhaar EP; Palen K; Riese MJ; Gershan J; Johnson BD; Dwinell MB
J Immunother Cancer; 2019 Apr; 7(1):115. PubMed ID: 31036082
[TBL] [Abstract][Full Text] [Related]
19. A CD40 Agonist and PD-1 Antagonist Antibody Reprogram the Microenvironment of Nonimmunogenic Tumors to Allow T-cell-Mediated Anticancer Activity.
Ma HS; Poudel B; Torres ER; Sidhom JW; Robinson TM; Christmas B; Scott B; Cruz K; Woolman S; Wall VZ; Armstrong T; Jaffee EM
Cancer Immunol Res; 2019 Mar; 7(3):428-442. PubMed ID: 30642833
[TBL] [Abstract][Full Text] [Related]
20. Cholecystokinin receptor antagonist alters pancreatic cancer microenvironment and increases efficacy of immune checkpoint antibody therapy in mice.
Smith JP; Wang S; Nadella S; Jablonski SA; Weiner LM
Cancer Immunol Immunother; 2018 Feb; 67(2):195-207. PubMed ID: 29043413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]